Skip to main content
SpringerLink
Log in

Dapagliflozin associated with higher risk of ketoacidosis in T2DM patients

  • Unknown
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • The Reporting Frequency of Ketoacidosis Events with Dapagliflozin from the European Spontaneous Reporting System: The DAPA-KETO Study Pharmaceuticals : 28 Mar 2022. Available from: URL: https://doi.org/10.3390/ph15030286

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dapagliflozin associated with higher risk of ketoacidosis in T2DM patients. Reactions Weekly 1900, 6 (2022). https://doi.org/10.1007/s40278-022-12358-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-12358-9

Search

Navigation